Coronavirus Live Count Map India
remove_red_eye 2812 Views
COVID-19 Vaccine Updates
Biofilm has often been cited as a key pathological factor in non-healing wounds. It therefore seems crucial to manage the biofilm in order to expedite wound healing and achieve the desired outcome.
A study by Scully and colleagues compared the clinical and in vitro performance of a next-generation antibiofilm silver dressing (NGAD) enriched with an antimicrobial dressing technology. This technology was developed even before wound biofilm was recognized as a clinical challenge.
Real-life assessments of hard-to-heal wounds, managed previously with cadexomer iodine (CI) dressings, and switched to NGAD, were evaluated. Electron, confocal and light microscopy images from a challenging, in vitro, exuding chronic wound model were also assessed.
Thirteen non-healing wounds previously managed with protocols including CI dressings were assessed. After a median of four weeks, switch to the NGAD was found to improve nine wounds and heal two wounds. There were accompanying improvements in wound bed appearance, with dressing usage being the same as or lower than before.
NGAD could prevent the development of Staphylococcus aureus-Pseudomonas aeruginosa biofilm over three days, contrary to CI dressing, which supported the development of biofilm once the active antimicrobial was used up from its carrier material. In clinical case studies, this exhaustion was shown as whiting out of the dressing with evidence of wound biofilm in samples obtained after dressing use. Two cases demonstrated positive wound and patient outcomes after the switch from a CI primary dressing to the NGAD in highly exuding and infected wounds.
The study demonstrated that the antibiofilm hydrofiber silver dressing seems to yield positive outcomes in managing challenging wounds.
Source: Scully R, Hurlow J, Walker M, et al. Clinical and in vitro performance of an antibiofilm Hydrofiber wound dressing. J Wound Care. 2018 Sep 2;27(9):584-592.